Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Tailored to Fit: Precision Medicine in Metastatic CRC



ReachMD Healthcare Image

Here’s how we can adopt biomarker testing into routine practice to personalize our treatment approach for patients with metastatic colorectal cancer.

  • Sponsored by

  • Overview

    Even though guidelines recommend biomarker testing at diagnosis with advanced or metastatic colorectal cancer (CRC), current rates of testing in clinical practice remain inadequate.1,2 Explore practical suggestions for addressing challenges in biomarker testing for metastatic CRC with Dr. Mark Lewis, Director of Gastrointestinal Oncology at Intermountain Health in Salt Lake City, Utah, and Dr. Kristen Ciombor, Associate Professor of Medicine at the Vanderbilt-Ingram Cancer Center in Nashville, Tennessee.

    The healthcare providers featured in this episode have been paid by Pfizer for their time.


    1.  Sepulveda AR, Hamilton SR, Allegra CJ, et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline summary from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology. J Oncol Pract. 2017;13(5):333-337. doi:10.1200/JOP.2017.022152
    2.  Iyer P, Deng M, Handorf EA, et al. Assessing Oncologists' Adoption of Biomarker Testing in Metastatic Colorectal Cancer Using Real-World Data. JNCI Cancer Spectr. 2022;6(6):pkac065. doi:10.1093/jncics/pkac065

    Continuing medical education credits are not available for this program.
    © 2023 Pfizer Inc. All rights reserved.  PP-UNP-USA-2090 June 2023

Schedule25 Sep 2023